4.3 Article

Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease

Related references

Note: Only part of the references are listed.
Article Gastroenterology & Hepatology

Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient

Niels Vande Casteele et al.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2013)

Article Gastroenterology & Hepatology

The duration of effect of infliximab maintenance treatment in paediatric Crohn's disease is limited

C. I. de Bie et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)

Review Gastroenterology & Hepatology

Review article: loss of response to anti-TNF treatments in Crohn's disease

S. Ben-Horin et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)

Article Gastroenterology & Hepatology

Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease

Casper Steenholdt et al.

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2011)

Article Gastroenterology & Hepatology

Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease

Waqqas Afif et al.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)

Review Gastroenterology & Hepatology

Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review

Javier P. Gisbert et al.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)

Article Gastroenterology & Hepatology

Long-term Outcome of Maintenance Infliximab Therapy in Children with Crohn's Disease

Jeffrey S. Hyoms et al.

INFLAMMATORY BOWEL DISEASES (2009)

Article Gastroenterology & Hepatology

Infliximab dependency in pediatric Crohn's disease: Long-term follow-up of an unselected cohort

Lissy de Ridder et al.

INFLAMMATORY BOWEL DISEASES (2008)

Review Pharmacology & Pharmacy

Clinical pharmacokinetics and use of infliximab

Ulrich Klotz et al.

CLINICAL PHARMACOKINETICS (2007)

Article Gastroenterology & Hepatology

Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease

Elana A. Maser et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)

Article Gastroenterology & Hepatology

Optimizing anti-TNF treatment in inflammatory bowel disease

P Rutgeerts et al.

GASTROENTEROLOGY (2004)

Article Medicine, General & Internal

Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease

F Baert et al.

NEW ENGLAND JOURNAL OF MEDICINE (2003)

Article Medicine, General & Internal

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

SB Hanauer et al.

LANCET (2002)